U.S. market Closed. Opens in 1 day 7 hours 3 minutes

ABCL | AbCellera Biologics Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue38.02M485.42M375.20M233.16M11.61M8.83M
Cost of RevenueN/A66.44M45.52M27.14M10.11M5.80M
Gross Profit38.02M418.99M329.69M206.01M1.50M3.03M
Operating Expenses275.23M191.92M107.79M41.66M13.95M7.99M
Selling, General & Admin75.18M66.75M48.76M15.75M4.01M2.86M
Research & Development175.66M107.88M62.06M29.39M10.11M5.80M
Other Operating Expenses24.39M17.29M-3.04M-3.48M-170.41K-675.51K
Operating Income-237.21M216.51M204.41M156.03M-4.12M-753.00K
Other Expenses / Income63.18M22.59M14.74M1.80M1.91M1.06M
Before Tax Income-174.03M239.10M219.15M157.83M-2.21M309.00K
Income Tax Expenses-27.63M80.58M65.69M38.91M209.20K1.27M
Net Income-146.40M158.52M153.46M118.92M-2.42M309.00K
Interest ExpensesN/A4.04M5.22M6.51M209.20K212.00K
Basic Shares Outstanding289.17M285.06M275.76M269.50M154.09M237.72M
Diluted Shares Outstanding289.17M314.83M318.29M269.50M154.09M237.72M
EBITDA-192.16M272.20M241.62M169.62M-397.42K165.00K
EBITDA Margin-505.35%56.07%64.40%72.75%-3.42%1.87%
EBIT-174.03M243.14M224.37M164.34M-2.00M1.80M
EBIT Margin-457.67%50.09%59.80%70.49%-17.24%20.33%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙